LLY
1,067.68
+0.83%↑
JNJ
205.97
+1.01%↑
ABBV
229.49
-2.82%↓
UNH
318.47
-0.28%↓
AZN
91.56
+0.6%↑
LLY
1,067.68
+0.83%↑
JNJ
205.97
+1.01%↑
ABBV
229.49
-2.82%↓
UNH
318.47
-0.28%↓
AZN
91.56
+0.6%↑
LLY
1,067.68
+0.83%↑
JNJ
205.97
+1.01%↑
ABBV
229.49
-2.82%↓
UNH
318.47
-0.28%↓
AZN
91.56
+0.6%↑
LLY
1,067.68
+0.83%↑
JNJ
205.97
+1.01%↑
ABBV
229.49
-2.82%↓
UNH
318.47
-0.28%↓
AZN
91.56
+0.6%↑
LLY
1,067.68
+0.83%↑
JNJ
205.97
+1.01%↑
ABBV
229.49
-2.82%↓
UNH
318.47
-0.28%↓
AZN
91.56
+0.6%↑
24h
Current
Min
Max
Income | -75M -544K |
|---|---|
Sales | 182K 26M |
P/E Sector Avg | 19.532 106.172 |
Profit margin | -2.087 |
Employees | 59 |
EBITDA | 73M 1.5M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +179.07% upside |
Market Cap | -56M 517M |
|---|---|
Previous open | 0 |
Previous close | 0 |
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
27 lut 2025, 15:29 UTC
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 24 USD 179.07%
High 26 USD
Low 21 USD
Based on 6 Wall Street analysts offering 12 month price targets forKemPharm Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
6 ratings
6
Buy
0
Hold
0
Sell
Based on 6 analysts giving stock ratings to KemPharm Inc - Dist in the past 3 months.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$